scholarly journals Identification of Potential Plasma Biomarkers for Abdominal Aortic Aneurysm Using Tandem Mass Tag Quantitative Proteomics

Proteomes ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 43 ◽  
Author(s):  
Anders Henriksson ◽  
Markus Lindqvist ◽  
Carina Sihlbom ◽  
Jörgen Bergström ◽  
Dan Bylund

Plasma biomarkers that identify abdominal aortic aneurysm (AAA) rupture risk would greatly assist in stratifying patients with small aneurysms. Identification of such biomarkers has hitherto been unsuccessful over a range of studies using different methods. The present study used an alternative proteomic approach to find new, potential plasma AAA biomarker candidates. Pre-fractionated plasma samples from twelve patients with AAA and eight matched controls without aneurysm were analyzed by mass spectrometry applying a tandem mass tag (TMT) technique. Eight proteins were differentially regulated in patients compared to controls, including decreased levels of the enzyme bleomycin hydrolase. The down-regulation of this enzyme was confirmed in an extended validation study using an enzyme-linked immunosorbent assay (ELISA). The TMT-based proteomic approach thus identified novel potential plasma biomarkers for AAA.

2011 ◽  
Vol 42 (5) ◽  
pp. 563-570 ◽  
Author(s):  
B. Pulinx ◽  
F.A.M.V.I. Hellenthal ◽  
K. Hamulyák ◽  
M.P. van Dieijen-Visser ◽  
G.W.H. Schurink ◽  
...  

The Lancet ◽  
2013 ◽  
Vol 381 ◽  
pp. S39
Author(s):  
S Ehsan ◽  
SE Slade ◽  
D Boocock ◽  
KE Herbert ◽  
RD Sayers ◽  
...  

2020 ◽  
Vol 3 ◽  
Author(s):  
Ronald L Dalman ◽  
Ying Lu ◽  
Kenneth W Mahaffey ◽  
Amanda J Chase ◽  
Jordan R Stern ◽  
...  

Abdominal aortic aneurysm (AAA) may lead to rupture and death if left untreated. While endovascular or surgical repair is generally recommended for AAA greater than 5–5.5 cm, the vast majority of aneurysms detected by screening modalities are smaller than this threshold. Once discovered, there would be a significant potential benefit in suppressing the growth of these small aneurysms in order to obviate the need for repair and mitigate rupture risk. Patients with diabetes, in particular those taking the oral hypoglycaemic medication metformin, have been shown to have lower incidence, growth rate, and rupture risk of AAA. Metformin therefore represents a widely available, non-toxic, potential inhibitor of AAA growth, but thus far no prospective clinical studies have evaluated this. Here, we present the background, rationale, and design for a randomised, double-blind, placebo-controlled clinical trial of metformin for growth suppression in patients with small AAA.


2013 ◽  
Vol 34 (suppl 1) ◽  
pp. 5937-5937
Author(s):  
S. M. Eken ◽  
E. Chernogubova ◽  
H. Jin ◽  
J. Roy ◽  
A. Hamsten ◽  
...  

2011 ◽  
Vol 7 (10) ◽  
pp. 2855 ◽  
Author(s):  
Tania Gamberi ◽  
Michele Puglia ◽  
Francesca Guidi ◽  
Francesca Magherini ◽  
Luca Bini ◽  
...  

2009 ◽  
Vol 102 ◽  
pp. S117
Author(s):  
A. Acosta Martin ◽  
A. Panchaud ◽  
M. Chwastyniak ◽  
B. Gallis ◽  
P. Amouyel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document